Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out

NEW YORK — Sixteen floors above Central Park, Kris White keeps his gentler pathogens behind an unlocked stainless steel freezer door, in brightly colored boxes caked with frost.

There’s an orange box of Zika, looking little different from a forgotten package of Trader Joe’s Butter Chicken, and a weakened form of SARS-CoV-2 in forest green. What White calls “the dangerous viruses” — wild-type SARS-CoV-2 and MERS, the camel-borne coronavirus with a 35% fatality rate  — are stored under tighter lockdown upstairs. In the basement here at Mount Sinai Medical Center, mice scurry around a depressurized vivarium, built so no air can escape.

White’s Upper East Side virus bodega is one of the last surviving remnants of a nationwide crash program created to design medicines against the world’s most dangerous viral threats.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In